Transforming Medicine
with Proven Products

Heart Failure Diuresis –
Where and When Needed

Our advanced precision pump technology enables cost-effective subcutaneous administration
of pharmaceuticals.

Taking the PICC
out of OPAT

Our convenient sc2Wear™ pump enables subcutaneous anytime anywhere delivery of drugs
that now require intravenous or intramuscular administration.

We are a pharmaceutical company developing a new and better way to administer some of the most important drugs used in medicine.

Heart Failure

Improving heart failure outcomes with the subcutaneous administration of furosemide.

Infectious Disease

Revolutionizing outpatient parenteral antibiotic therapy treatment by means of subcutaneous delivery.

Why scPharmaceuticals

Changing the Heart Failure Treatment Paradigm with the sc2Wear™ pump

scPharmaceuticals - working to enable better care for less through the subcutaneous administration of proven pharmaceuticals.

Learn More


Go to News & Events

Supernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals Board of Directors

FOR IMMEDIATE RELEASE: LEXINGTON, MA./PRNewswire/ — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Jack A. Khattar has been appointed to scPharmaceuticals’ Board of Directors.


scPharmaceuticals Announces Expansion of Executive Team

FOR IMMEDIATE RELEASE: LEXINGTON, MA./PRNewswire/ – scPharmaceuticals, Inc. today announced two executive appointments reflecting the evolution of the company from a development-oriented company to a commercially-focused organization.


scPharmaceuticals Announces Positive Results from Pivotal Trial of Second Program – Subcutaneous Ceftriaxone for Treatment of Bacterial Infections

FOR IMMEDIATE RELEASE: LEXINGTON, MA./PRNewswire/ — scPharmaceuticals, Inc., announced today that the pivotal trial for its ceftriaxone program met the targeted end-points. The primary end-point for the study is non-inferior antimicrobial coverage when compared to the same dose given by intravenous infusion.